FDA Expands Age Indication for Staar EVO/EVO+ Visian ICL

FDA broadens age indication for Staar’s EVO/EVO+ Visian ICL

Staar Surgical Company announces that the U.S. Food and Drug Administration approves an expanded age indication for its EVO and EVO+ Visian Implantable Collamer Lenses (ICL), widening the pool of patients eligible for the implanted refractive-correction devices. The lenses, which provide a reversible, implantable option for correcting myopia and other refractive errors, now carry regulatory backing for use across newly authorized ages, although the company’s release does not specify the precise age boundaries. The decision formally permits surgeons and eye-care professionals to consider the ICL for individuals who previously fell outside the prior age limits, potentially changing candidacy assessments in refractive clinics.

Clinicians and specialty practices respond by re-evaluating patient selection pathways and preoperative protocols to incorporate the expanded indication. The ICL’s appeal—preserving corneal tissue and offering a reversible solution compared with corneal refractive surgery—positions it as an alternative for patients and surgeons weighing safety, predictability and long-term vision outcomes. Ophthalmologists are seeking updated labeling, clinical guidance and training materials to align informed consent discussions and to ensure appropriate follow-up, particularly for younger or older patients added under the new indication.

Regulatory approval also prompts attention to real-world safety monitoring and post-market data collection as physicians and health systems gather outcomes across a broader demographic. Longitudinal data on vault stability, endothelial cell counts, intraocular pressure and cataract incidence remain central to risk–benefit discussions, and the expanded label increases the imperative for robust surveillance and peer-reviewed reporting. Professional societies and registries are expected to play a role in tracking adoption patterns and complications as use extends to newly eligible age groups.

Surgeon training, supply logistics and payer engagement

Staar is preparing to update educational programs and commercial materials for surgeons and clinics to support the wider indication, and to coordinate supply and distribution so clinics can meet anticipated demand. The company is likely to accelerate hands-on surgeon training and to disseminate clinical decision tools that help determine candidacy under the new age parameters.

Reimbursement and coverage discussions are also rising in importance as patients and providers seek clarity on insurance eligibility for the ICL under the expanded indication. Payers, analysts and clinicians are watching post-market evidence and insurer policies closely to determine how coverage and real-world adoption evolve.